← Back to all trials
Recruiting
NCT06869551
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Conditions: Juvenile Psoriatic Arthritis
Sex: All
Ages: 5 Years – 17 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 60
Sponsor: Bristol-Myers Squibb
Location: Local Institution - 0038 Lancaster California
Summary
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Eligibility Criteria
Inclusion Criteria
* Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
* Participants must have at least three joints that are affected by arthritis.
* Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.
Exclusion Criteria
* Participants must not have been diagnosed with JPsA before 5 years of age.
* Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
* Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
* Other protocol-defined Inclusion/Exclusion criteria apply.
Source: ClinicalTrials.gov (NCT06869551). StuddyBuddy aggregates publicly available trial information.
